How are dealmakers allocating risk of financing failure in M&A deals?

In this comprehensive study, our team of attorneys examined the reverse break-up fees and specific performance provisions in 68 public company merger agreements for debt-financed deals from 2012 with a signing value of at least $100 million.

Get data-driven analysis of the latest trends in public deal remedies, including:

  • How deal size and buyer type impact the choice of remedy.
  • Reverse break-up fee sizes as a percentage of deal value.
  • Approaches to drafting equitable and monetary remedies among strategic and financial buyers.
  • Drafting formulations for financing covenants and their connection to the form of specific performance remedy.
  • Which "Xerox provisions" are lenders most commonly insisting on, and more.

Fill out the form on the right to receive your complimentary copy now.

Sample Excerpt:

{ "siteName" : "PLC", "objType" : "MarketingPage", "objID" : "1247353483981", "objName" : "Deal Study", "userID" : "2", "objUrl" : "", "pageType" : "", "academicUserID" : "", "contentAccessed" : "true", "analyticsPermCookie" : "25c52fb8f:15157ead928:-42e2", "analyticsSessionCookie" : "25c52fb8f:15157ead928:-42e1", "statisticSensorPath" : "" }